Navigation Links
Silence Therapeutics Issued New U.S. Patent Covering Fundamental RNA Interference Technology Currently in Several Clinical Trials

LONDON, Feb. 23, 2011 /PRNewswire/ -- Silence Therapeutics plc (AIM: SLN) ("Silence" or the "Company") announces the issuance of United States patent 7,893,245, titled "Interfering RNA Molecules," by the United States Patent and Trademark Office (USPTO).  The issued patent, which represents a continuation of previously issued U.S. Patent Number 7,452,987, covers chemically modified RNAi molecules with defined positional modifications including siRNA molecules that are blunt ended, as well as molecules with one or more overhangs.  Importantly, this latest patent broadens Silence's protection of these RNAi molecules to those with a chemically modified core length between 17 and 29 nucleotides including the company's portfolio of 25mer siRNA sequences.  This patented siRNA technology forms the foundation for AtuRNAi, Silence's propriety RNAi molecules. Various therapeutics incorporating Silence's AtuRNAi technology are currently being studied in five ongoing clinical trials conducted by Silence Therapeutics and other industry leaders.

"The extended protection for our RNAi technology, particularly the expanded coverage of our AtuRNAi platform, reinforces the meaningful advances Silence Therapeutics is making in the field of RNAi therapeutics.  The AtuRNAi technology is actively being advanced in multiple Phase II clinical studies by Quark and in our own Phase I trial and to date more than 200 patients have been dosed with AtuRNAi with no reported safety issues," stated Philip Haworth, Ph.D., chief executive officer of Silence Therapeutics.  "The value of the AtuRNAi technology is an essential component of all of our internal and partnered programs.  With the extended protection for the AtuRNAi technology, which can be combined with our broadly protected structural modification technology (the 'Zamore Design Rules,'), we and our partners are able to invest in product development more aggressively."  

In related intellectual property news, Silence also announces the issuance of United States patent 7,893,243, titled "Composition and Methods of RNAi Therapeutics for Treatment of Cancer and Other Neovascularization Diseases," by the United States Patent and Trademark Office (USPTO).  This issued patent is broadly directed to a double stranded, double blunt ended siRNA sequence against the validated cancer target vascular endothelial growth factor (VEGF).  VEGF has been demonstrated to play an important role in the underlying causes of various cancers including abnormal angiogenesis and uncontrolled cell division.  The active pharmaceutical ingredient covered by the issued patent is a potent 25mer siRNA, with or without chemical modification, further demonstrating Silence's continued ability to secure meaningful intellectual property protection for its portfolio of 25mer sequences.  

Silence Therapeutics is executing a proactive strategy to continue to build and strengthen a global, diverse and competitive intellectual property portfolio that provides the Company and its partners with a strong proprietary position in the RNAi therapeutics space.  The Company believes that it will continue to make significant progress in these efforts as it expects additional RNAi patents to be issued in Japan, the United States and Europe during 2011.  At present, Silence's global patent portfolio contains issued patents and pending applications covering strategic areas of RNAi therapeutic development including multiple proprietary siRNA delivery technologies, potent siRNA sequences specific for high-value disease targets and key RNAi sequence and chemical modifications.

Notes for editors

About Silence Therapeutics plc (

Silence Therapeutics plc (AIM: SLN) is a leading global biotechnology company dedicated to the discovery, development and delivery of targeted, systemic RNA interference (RNAi) therapeutics for the treatment of serious diseases.  The company possesses multiple proprietary short interfering RNA (siRNA) delivery technology platforms including AtuPLEX™, a system that enables the functional delivery of siRNA molecules to targeted diseased tissues and cells, while increasing their bioavailability and intracellular uptake.  A second, complementary delivery technology known as PolyTran™ uses a library of novel peptide-based biodegradable polycationic polymers for systemic siRNA administration.  Additionally, the company has a platform of novel siRNA molecules, AtuRNAi, which provide a number of advantages over conventional siRNA molecules, including reduced cytokine induction and decreased manufacturing costs.  Silence's unique RNAi assets also include structural features for a next generation of RNAi molecules and additional proprietary siRNA sequences against more than 50 highly valued oncology and other disease targets.

The Company's lead internal drug candidate is Atu027, a liposomal AtuRNAi formulation in clinical development for systemic cancer indications and one of the most clinically advanced RNAi therapeutics in the area of oncology. Silence is currently conducting an open-label, single-centre, dose-escalation Phase I study with Atu027 in patients with advanced solid tumors involving single, as well as, repeated intravenous administration. The study is expected to be completed in the second half of 2011.

The Company's RNAi therapeutic platform has received key validation through multiple partnerships with pharmaceutical companies including AstraZeneca, Dainippon Sumitomo, Pfizer, and Quark. Silence is actively pursuing the establishment of additional partnerships.

Forward-Looking Statements

This press release includes forward-looking statements that are subject to risks, uncertainties and other factors. These risks and uncertainties could cause actual results to differ materially from those referred to in the forward-looking statements. All forward-looking statements are based on information currently available to Silence Therapeutics and Silence Therapeutics assumes no obligation to update any such forward-looking statements.

SOURCE Silence Therapeutics plc
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Silence Therapeutics Provides Year-end Update
2. Silence Therapeutics Issued New Patents Covering siRNA Sequences for RNA Interference Therapeutics
3. Silence Therapeutics and AstraZeneca Extend siRNA Development Collaboration
4. Silence Therapeutics to Merge with Intradigm Corp to Create Leading RNAi Therapeutics Company
5. Silence Therapeutics to Receive $1.9m Milestone Payment as Pfizer and Quark Commence Phase II Trial
6. Silence Therapeutics Announces Board Changes
7. Recent siRNA Research Publications Support Silence Therapeutics Combined Development Approach
8. Video: Actress and New Mom Keri Russell Joins PKIDs to Launch Silence the Sounds of Pertussis Campaign
9. Actress and New Mom Keri Russell Joins PKIDs to launch Silence the Sounds of Pertussis Campaign
10. Cornerstone Therapeutics to Host Fourth Quarter and Full Year 2010 Conference Call
11. Echo Therapeutics Reports Symphony™ tCGM System Ahead of Schedule
Post Your Comments:
(Date:6/23/2016)... 23, 2016 Roche (SIX: RO, ROG; OTCQX: ... its Elecsys BRAHMS PCT (procalcitonin) assay as a dedicated ... shock. With this clearance, Roche is the first IVD ... solution for sepsis risk assessment and management. ... and PCT levels in blood can aid clinicians in ...
(Date:6/23/2016)... DUBLIN , June 23, 2016 ... "Key Pharma News Issue 52" report to their offering. ... need in influenza treatment creates a favourable commercial environment for ... and growing patient base that will serve to drive considerable ... flu vaccine would serve to cap sales considerably, but development ...
(Date:6/23/2016)... Ill. and INDIANAPOLIS , ... students receiving a Lilly Diabetes Tomorrow,s Leaders Scholarship is ... 2016 scholarship winners, announced today online at ... let type 1 diabetes stand in the way of ... has supported the Foundation,s scholarship program since 2012, and ...
Breaking Medicine Technology:
(Date:6/27/2016)... (PRWEB) , ... June 27, 2016 , ... "FCPX editors ... customizable inside of Final Cut Pro X," said Christina Austin - CEO of Pixel ... style. Final Cut Pro X users can now reveal the media of ...
(Date:6/27/2016)... ... June 27, 2016 , ... ... patient payment industry today announced its strategic partnership with Connance, a healthcare ... , The two companies’ proven, proprietary technology combine to provide health systems, ...
(Date:6/27/2016)... ... June 27, 2016 , ... recently awarded their highest ... . , Millions of individuals in the United States and Canada wear eyeglasses. Once ... to both correct vision and make a fashion statement. Even celebrities use glasses as ...
(Date:6/26/2016)... ... June 26, 2016 , ... On June 10-11, 2016, A Forever Recovery, a ... and World’s Longest Breakfast Table in Battle Creek, MI, where the rehabilitation facility is ... to some of the world’s leading providers of cereal and other breakfast foods. Its ...
(Date:6/26/2016)... ... June 26, 2016 , ... PawPaws brand pet ... product that was developed to enhance the health of felines. The formula is all-natural ... two main herbs in the PawPaws Cat Kidney Support Supplement Soft Chews ...
Breaking Medicine News(10 mins):